Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial
Carl E. Allen; Theodore W. Laetsch; Rajen Mody; Meredith S. Irwin; Megan S. Lim; Peter C. Adamson; Nita L. Seibel; D. Williams Parsons; Y. Jae Cho; Katherine Janeway
Author Information: Texas Children’s Cancer Center, Texas Children’s Hospital, Houston, TX (CEA, DWP); Division of Pediatric Hematology-Oncology, Department of Pediatrics (CEA, DWP), Department of Molecular and Human Genetics (DWP), and Human Genome Sequencing Center (DWP), Baylor College of Medicine, Houston, TX; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX (TWL); Pauline Allen Gill Center for Cancer and Blood Disorders, Children’s Health, Dallas, TX (TWL); Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI (RM); Department of Pediatrics, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada (MSI); Department of Pathology and Laboratory Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania and Children’s Hospital of Philadelphia, Philadelphia, PA (MSL); Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA (PCA); Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD (NLS); Division of Pediatric Neurology, Doernbecher Children’s Hospital, Portland, OR (YJC); Knight Cancer Institute, Oregon Health and Science University, Portland, OR (YJC); Department of Pediatric Oncology, Dana-Farber/Boston Children’s Cancer Center and Blood Disorder Center, Boston, MA (KJ).
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.